Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL VIRAL VECTOR AND VACCINE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL VIRAL VECTOR AND VACCINE MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL VIRAL VECTOR AND VACCINE MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EPIDEMIOLOGY
7 INDUSTRY INSIGHTS
8 REGULATORY SCENARIO
9 GLOBAL VIRAL VECTOR AND VACCINE MARKET, BY TYPE
9.1 OVERVIEW
9.2 ADENOVIRUS
9.3 RETROVIRUS
9.4 VACCINE VIRUS
9.5 ADENO-ASSOCIATED VIRUS (AAV)
9.6 LENTIVIRUS
9.7 HERPES SIMPLEX VIRUSES
9.8 ALPHAVIRUSES
9.9 OTHERS
10 GLOBAL VIRAL VECTOR AND VACCINE MARKET, BY EXPRESSION SYSTEM
10.1 OVERVIEW
10.2 TRANSIENT
10.3 STABLE
11 GLOBAL VIRAL VECTOR AND VACCINE MARKET, BY WORKFLOW
11.1 OVERVIEW
11.2 UPSTREAM PROCESSING
11.2.1 VECTOR AMPLIFICATION
11.2.2 VECTOR RECOVERY
11.3 DOWNSTREAM PROCESSING
11.3.1 PURIFICATION
11.3.2 FILLS FINISH
12 GLOBAL VIRAL VECTOR AND VACCINE MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 ANTISENSE & RNAI
12.3 GENE THERAPY
12.4 CELL THERAPY
12.5 VACCINOLOGY
12.6 OTHER
13 GLOBAL VIRAL VECTOR AND VACCINE MARKET, BY DISEASE
13.1 OVERVIEW
13.2 CANCER
13.3 GENETIC DISORDERS
13.3.1 THALASSEMIA
13.3.2 CYSTIC FIBROSIS
13.3.3 TAY-SACHS DISEASE
13.3.4 SICKLE CELL ANEMIA
13.3.5 OTHERS
13.4 INFECTIOUS DISEASES
13.4.1 MEASLES VIRUS
13.4.2 VESICULAR STOMATITIS VIRUS
13.4.3 NOVEL ADENOVIRUSES
13.4.4 CYTOMEGALOVIRUS
13.4.5 OTHERS
13.5 OTHERS
14 GLOBAL VIRAL VECTOR AND VACCINE MARKET, BY END USER
14.1 OVERVIEW
14.2 PHARMACEUTICAL COMPANIES
14.2.1 SMALL SIZE ENTERPRISE
14.2.2 MEDIUM SIZE ENTERPRISE
14.2.3 LARGE SIZE ENTERPRISE
14.3 BIOPHARMACEUTICAL COMPANIES
14.3.1 SMALL SIZE ENTERPRISE
14.3.2 MEDIUM SIZE ENTERPRISE
14.3.3 LARGE SIZE ENTERPRISE
14.4 CONTRACT RESEARCH ORGANISATION (CRO)
14.4.1 SMALL SIZE ENTERPRISE
14.4.2 MEDIUM SIZE ENTERPRISE
14.4.3 LARGE SIZE ENTERPRISE
14.5 ACADEMIC & RESEARCH INSTITUTES
14.6 OTHER
15 GLOBAL VIRAL VECTOR AND VACCINE MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL VIRAL VECTOR AND VACCINE MARKET, BY GEOGRAPHY
16.1 GLOBAL VIRAL VECTOR AND VACCINE MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.1.1 NORTH AMERICA
16.1.1.1. U.S.
16.1.1.2. CANADA
16.1.1.3. MEXICO
16.1.2 EUROPE
16.1.2.1. GERMANY
16.1.2.2. U.K.
16.1.2.3. ITALY
16.1.2.4. FRANCE
16.1.2.5. SPAIN
16.1.2.6. RUSSIA
16.1.2.7. SWITZERLAND
16.1.2.8. TURKEY
16.1.2.9. BELGIUM
16.1.2.10. NETHERLANDS
16.1.2.11. DENMARK
16.1.2.12. SWEDEN
16.1.2.13. POLAND
16.1.2.14. NORWAY
16.1.2.15. FINLAND
16.1.2.16. REST OF EUROPE
16.1.3 ASIA-PACIFIC
16.1.3.1. JAPAN
16.1.3.2. CHINA
16.1.3.3. SOUTH KOREA
16.1.3.4. INDIA
16.1.3.5. SINGAPORE
16.1.3.6. THAILAND
16.1.3.7. INDONESIA
16.1.3.8. MALAYSIA
16.1.3.9. PHILIPPINES
16.1.3.10. AUSTRALIA
16.1.3.11. NEW ZEALAND
16.1.3.12. VIETNAM
16.1.3.13. TAIWAN
16.1.3.14. REST OF ASIA-PACIFIC
16.1.4 SOUTH AMERICA
16.1.4.1. BRAZIL
16.1.4.2. ARGENTINA
16.1.4.3. REST OF SOUTH AMERICA
16.1.5 MIDDLE EAST AND AFRICA
16.1.5.1. SOUTH AFRICA
16.1.5.2. EGYPT
16.1.5.3. BAHRAIN
16.1.5.4. UNITED ARAB EMIRATES
16.1.5.5. KUWAIT
16.1.5.6. OMAN
16.1.5.7. QATAR
16.1.5.8. SAUDI ARABIA
16.1.5.9. REST OF MEA
16.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL VIRAL VECTOR AND VACCINE MARKET, SWOT AND DBMR ANALYSIS
18 GLOBAL VIRAL VECTOR AND VACCINE MARKET, COMPANY PROFILE
18.1 NOVASEP
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 MERCKKGAA
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 SARTORIUS AG
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 SIRION-BIOTECH GMBH
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 MAXCYTE
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 CREATIVE BIOLABS
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 UNIQURE N.V.
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 WAISMAN BIOMANUFACTURING
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 CREATIVE-BIOGENE
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.1 ALDEVRON
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 ADDGENE
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 OXFORD BIOMEDICA
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 THERMO FISHER SCIENTIFIC INC
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 PROBIOGEN AG
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 IOSBIO
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 IDT BIOLOGIKA
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 REITHERA SRL
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 CHARLES RIVER LABORATORIES
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 FUJIFILM DIOSYNTH BIOTECHNOLOGIES
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.2 SPARK THERAPEUTICS INC.
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 ABL INC.
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 GENERAL ELECTRIC
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 PFIZER INC.
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPMENTS
18.25 LONZA
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPMENTS
18.26 KANEKA CORPORATION
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
18.26.5 RECENT DEVELOPMENTS
18.27 REGENXBIO
18.27.1 COMPANY OVERVIEW
18.27.2 REVENUE ANALYSIS
18.27.3 GEOGRAPHIC PRESENCE
18.27.4 PRODUCT PORTFOLIO
18.27.5 RECENT DEVELOPMENTS
18.28 FINVECTOR
18.28.1 COMPANY OVERVIEW
18.28.2 REVENUE ANALYSIS
18.28.3 GEOGRAPHIC PRESENCE
18.28.4 PRODUCT PORTFOLIO
18.28.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
